Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (1298)	1/3/2000 11:42:00 PM
From: RCMac	Read Replies (2) \| Respond to of 3202

>> <Rocketman> Absolutely ditto<< Absolutely ditto. Thanks, Rman. --RCM

To: LLCF who wrote (1298)	1/10/2000 9:39:00 AM
From: lwd	Read Replies (1) \| Respond to of 3202

David, Just documenting latest news. No need to reply. *********************************************************** Monday January 10, 7:01 am Eastern Time Company Press Release SOURCE: Incyte Pharmaceuticals, Inc. Incyte and Bayer Enter Into Genomic Partnership for Access to LifeSeq Gold For Use in Therapeutic Protein Drug Discovery PALO ALTO, Calif. and BERKELEY, Calif., Jan. 10 /PRNewswire/ -- Incyte Pharmaceuticals, Inc. (Nasdaq: INCY - news), a leading provider of genomic information, and Bayer Corporation announced today that the two companies have entered into an agreement whereby Incyte will provide Bayer with access to Incyte's LifeSeq© Gold database for therapeutic protein discovery. As a LifeSeq Gold subscriber, Bayer will have access to Incyte's extensive patent portfolio, which currently contains 481 issued and allowed full-length gene patents and patent filings covering over 50,000 unique genes. Incyte could receive future milestone payments and royalties on sales of products developed with Incyte technology and database information. Financial terms were not disclosed. Bayer's worldwide center for biotechnology research, development and manufacturing, located in Berkeley, California, is dedicated to using genomics to further the discovery and development of therapeutic proteins. Many serious illnesses are the result of the body under producing specific proteins, or in some cases producing undesirable proteins. Disease symptoms that result from proteins being under produced require the use of therapeutic proteins to counteract the deficiency. LifeSeq Gold is a powerful platform that provides researchers with the best view of the genome. This integrated easy to use database combines EST, full-length sequence, and expression information. Also included in a LifeSeq Gold subscription is access to high-quality sequence verified cDNA clones, or copies of genes, which researchers can obtain to conduct further studies. Currently an estimated 90 percent of the expressed genes within the human genome can be found in LifeSeq Gold. ``We have been impressed with Incyte's technology and accomplishments in providing genomic information and view the agreement as an important step in our continuing to create an innovative pipeline of new products,' said Wolf-Dieter Busse, Bayer's Senior Vice President for Biotechnology R&D. ``Bayer recognizes the inherent value of genomics and its significant role in the discovery and development of new drugs,' said Roy A. Whitfield, Chief Executive Officer of Incyte. ``We are pleased to grant access to our industry leading gene patent portfolio and clone archive to a proficient and experienced therapeutic protein product development company such as Bayer.' Bayer Corporation is a research-based company with major businesses in health care and life sciences and chemicals. The company had 1998 sales of $8.1 billion and employs more than 23,000 people. Bayer Corporation, with headquarters in Pittsburgh, is a member of the worldwide Bayer Group, a $31 billion international life sciences, polymers and specialty chemicals group based in Leverkusen, Germany. Incyte Pharmaceuticals, Inc. is a leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases, genomic data management software, microarray-based gene expression services, related reagents and services. These products and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. For more information, visit Incyte's web site at www.incyte.com. Except for the historical information contained herein, the matters set forth in this press release, are forward-looking statements within the meaning of the ``safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. For a discussion of factors that may cause results to differ, see Incyte's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 1999. Incyte disclaims any intent or obligation to update these forward-looking statements. SOURCE: Incyte Pharmaceuticals, Inc.